Evidence map›Paper›PMID 42800861›Full record

ArticleBMC microbiology2026

Beyond lethal doses: sub-MIC levels of multi-class antibiotics induce species- and isolate-dependent biofilm inhibition in gram-negative pathogens.

Raghda Elawady, Aliaa G Aboulela, Ahmed N Amer, Abeer A Ghazal, Ahmed Gaballah

Abstract read
In one paragraph

Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Raghda ElawadyDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt. Mri.raghda.m.microbiology18@alexu.edu.eg.
Aliaa G AboulelaDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt.ORCID http://orcid.org/0000-0002-2923-1027
Ahmed N AmerDepartment of Pharmaceutical Microbiology and Immunology, Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria University, Alexandria, Egypt.ORCID http://orcid.org/0000-0003-3610-4592
Abeer A GhazalDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt.ORCID http://orcid.org/0000-0001-8530-4879
Ahmed GaballahDepartment of Microbiology, Medical Research Institute, Alexandria University, Alexandria, Egypt.ORCID http://orcid.org/0000-0002-9038-6597

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiofilm-associated infections remain a major clinical challenge due to their intrinsic tolerance to antimicrobial therapy. Sub-minimum inhibitory concentrations (sub-MICs) of antibiotics are frequently encountered in vivo, particularly at sites of infection and on indwelling medical devices. However, their influence on biofilm formation is controversial, with evidence of both stimulatory and inhibitory effects. Clarifying these responses may reveal novel therapeutic opportunities for managing nosocomial biofilm-related infections. This study aims to investigate the effects of three sub-MIC concentrations (25%, 50%, and 75% of MIC) of five antibiotic classes on biofilm formation in Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae using two distinct biofilm quantification methods. MATERIALS AND

methodsIn this study, the effects of 5 different antimicrobial agents, namely, azithromycin, gentamicin, ciprofloxacin, doxycycline, and imipenem, at different sub-MIC concentrations (12.5%, 25%, and 50% of MIC) were tested on 5 different clinical isolates of P. aeruginosa, E. coli, and K. pneumoniae. Clinical isolates were exposed to sub-MIC levels of antibiotics in a standardized biofilm assay, with statistical comparisons conducted to determine significant biofilm modulation using crystal violet (CV) staining to measure total biomass accumulation and quantitative PCR (qPCR) to assess qPCR-derived genome-equivalent DNA abundance within biofilms. qPCR detects DNA originating from viable, dead, damaged, or lysed cells, as well as extracellular DNA (eDNA).

resultsAcross the 75 tested conditions (5 antibiotics × 3 sub-MIC concentrations × 5 clinical isolates per species), sub-inhibitory antibiotic exposure produced pronounced, species- and target-dependent biofilm responsiveness varied by species: P. aeruginosa demonstrated the highest biomass modulation (62% CV significance), E. coli exhibited the greatest molecular responsiveness (55% qPCR significance), and K. pneumoniae showed lower overall modulation (47% CV, 32% qPCR significance). Imipenem exerted the highest biomass suppression in P. aeruginosa (80% CV vs. 13% qPCR inhibition), whereas doxycycline predominantly reduced genome equivalents in P. aeruginosa (73% qPCR vs. 7% CV inhibition). In E. coli, azithromycin produced peak biomass inhibition (73% CV vs. 7% qPCR inhibition), while gentamicin led to molecular suppression (60% qPCR vs. 27% CV inhibition). In K. pneumoniae, azithromycin and ciprofloxacin directed to biomass inhibition (both 40% CV), while azithromycin produced the highest qPCR reduction (33% qPCR). Bidirectional modulation was widespread across drug classes. Azithromycin acted as a primary inducer in P. aeruginosa (80% CV, 67% qPCR induction), while imipenem shifted from a biomass inhibitor in P. aeruginosa (80% CV inhibition) to a primary inducer in K. pneumoniae (47% CV, 60% qPCR induction). Unidirectional responses were drug- and method-specific, such as imipenem in P. aeruginosa CV (80% inhibition) and doxycycline in P. aeruginosa qPCR (73% inhibition).

conclusionThis study demonstrates that sub-MIC exposure produces heterogeneous, antibiotic-, species-, isolate-, concentration-, and method-dependent biofilm responses that diverge between structural matrix accumulation and genomic abundance. Therefore, our findings highlight that sub-MIC exposures demand a multi-assay diagnostic framework to accurately evaluate biofilm-associated drug responses.

Indexed as

Anti-Bacterial AgentsBiofilmsGram-Negative BacteriaEscherichia coliHumansKlebsiella pneumoniaeMicrobial Sensitivity TestsPseudomonas aeruginosaAnti-Bacterial AgentsBiofilm modulationCrystal violetDNA abundanceInhibitionMatrixPCRSub‑MIC

Identifiers

PMID42800861
PMCPMC13615587

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.